LQDA
Liquidia Corp
$81.45
+1.98 (+2.49%)
At close · Jul 9
Market Cap
$6.95B
Shares
88,928,099
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$158.32M
+1031.2%
FY2025
Net Income
-$68.92M
+46.3%
FY2025
Gross Margin
58%
-25.5pp
FY2024
Operating Margin
-32.45%
+834.2pp
FY2025
Diluted EPS
-$0.80
+50.9%
FY2025
Operating Cash Flow
-$35.69M
+61.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2027 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|
| $1B | $288.07M | $158.32M | $14M | $17.49M | $15.94M | $12.85M | $739.63K | $8.07M | |
| — | $5.93M | — | $5.88M | $2.89M | $2.86M | $3.02M | $237.71K | — | |
| — | $8.22M | — | $8.12M | $14.6M | $13.08M | $9.83M | $501.92K | — | |
| — | — | — | 58% | 83.49% | 82.06% | 76.48% | 67.86% | — | |
| — | $44.88M | $39.28M | $47.84M | $43.24M | $19.44M | $20.52M | $32.22M | $40.49M | |
| — | $91.38M | — | $81.57M | $44.74M | $32.41M | $23.11M | $27.37M | $13.6M | |
| — | $174.05M | $157.18M | $81.57M | $44.74M | — | — | — | — | |
| — | — | $200K | $300K | $300K | $700K | $1.1M | — | — | |
| — | $1.57M | $1.53M | $2.2M | $2.18M | $3.65M | $5.61M | $3.13M | $2.57M | |
| — | $242.51M | $209.7M | $135.29M | $90.87M | $54.71M | $46.65M | $59.83M | $54.9M | |
| — | $45.55M | -$51.38M | -$121.29M | -$73.38M | -$38.77M | -$33.8M | -$59.09M | -$46.82M | |
| — | — | -32.45% | -866.63% | -419.62% | -243.3% | -262.95% | -7989.03% | -580.07% | |
| — | $47.13M | -$49.85M | -$119.1M | -$71.21M | -$35.12M | -$28.19M | -$55.96M | -$44.26M | |
| — | $26M | $24.17M | $14.65M | $6.27M | $2.34M | $762K | $858K | $1.37M | |
| — | $6.67M | $6.62M | $7.65M | $3.47M | $1.09M | $33K | $184.36K | $613.72K | |
| — | -$19.33M | -$17.55M | -$7M | -$5.12M | -$2.25M | -$782K | -$673.64K | -$759.91K | |
| — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| — | $22.31M | -$68.92M | -$128.29M | -$78.5M | -$41.02M | -$34.58M | -$59.76M | -$47.58M | |
| — | — | -43.53% | -916.63% | -448.89% | -257.39% | -269.03% | -8080.11% | -589.48% | |
| USD/shares | — | — | -$0.80 | -$1.63 | -$1.21 | -$0.67 | -$0.70 | -$1.76 | — |
| USD/shares | — | — | -$0.80 | -$1.63 | -$1.21 | -$0.67 | -$0.70 | -$1.76 | -$2.57 |
| shares | — | — | 86.06M | 78.71M | 64.99M | 60.96M | 49.68M | 33.89M | 18.48M |
| shares | — | — | 86.06M | 78.71M | 64.99M | 60.96M | 49.68M | 33.89M | 18.48M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
479.12×
Drug Manufacturers - Specialty & Generic median 21.17×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Single Reportable Segment | $158,320,000 | $13,996,000 | $17,488,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Product | $148,288,000 | — | — | — | — |
| Service | $10,032,000 | $13,996,000 | $17,488,000 | $739,628 | $0 |
| Collaboration | — | — | — | $0 | $8,072,120 |
| Research and Development Services | — | — | — | $0 | $200 |
| Royalty | — | — | — | $0 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Single Reportable Segment | -$51,376,000 | -$121,294,000 | -$73,384,000 |
Operating Margin by Segment (%)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Single Reportable Segment | -32.5% | -866.6% | -419.6% |
Key facts
CIK
1819576
CUSIP
53635D202
13F (30d)
12 filings
12 filers
Visit website
Investor relations